Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma.

Open Heart · 2019 · PMC6593195 · PMID 31297226

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

approached significancep=0.062so close (0.05 < p ≤ 0.1)

After adjustment for multiple comparisons, the interactions remained significant for the relationships between sex and dexrazoxane on LVIDD (p=0.011) and LVIDS (p<0.001), approached significance for SF (p=0.062) early after therapy, and remained significant for LVIDD (p=0.006) and LVIDS (p<0.001) 1–2 years post-therapy.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.